High-dose Dual Therapy for Treatment of Helicobacter pylori Infection: A Meta-analysis of Randomized Controlled Trials
10.3969/j.issn.1008-7125.2021.11.004
- Author:
Linglong GUO
1
;
Mianli LI
1
;
Juanjuan LI
2
;
Jingwei LI
2
;
Xiaoyan JIANG
2
;
Chunhong ZHANG
2
;
Bin HUANG
2
Author Information
1. The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine
2. Department of Spleen and Stomach, Shenzhen Hospital of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Helicobacter pylori;
High-Dose Dual Therapy;
Medication Compliance;
Meta-Analysis;
Safety
- From:Chinese Journal of Gastroenterology
2021;26(11):663-670
- CountryChina
- Language:Chinese
-
Abstract:
Background: High-dose dual therapy (HDDT) is a novel regimen for the eradication of Helicobacter pylori (Hp) infection, however, its efficacy and safety remain unclear. Aims: To evaluate the efficacy, safety and compliance of HDDT for Hp eradication. Methods: Randomized controlled trials (RCTs) on HDDT for eradication of Hp infection were retrieved from PubMed, Embase, The Cochrane Library, Web of Science from the date of database establishment to October 2020. Literatures were enrolled according to the inclusion and exclusion criteria, and the data were extracted. RevMan 5.2 software was used for performing meta-analysis. Results: Nine RCTs including 2 627 patients were included. Meta-analysis results showed that no significant differences in ITT eradication (85.4% vs. 79.8%, RR=1.03, 95% CI: 0.96-1.10, P=0.40), PP eradication (88.7% vs. 83.4%, RR=1.01, 95% CI: 0.95-1.08, P=0.68), and compliance (96.5% vs. 95.9%, RR=1.01, 95% CI: 0.99-1.02, P=0.37) were found between HDDT and the guideline-recommended regimens, however, the incidence of adverse events was significantly decreased in HDDT (15.3% vs. 27.0%, RR=0.57, 95% CI: 0.42-0.76, P=0.000 2). Conclusions: There are no significant differences in eradication rates and compliance between HDDT and the guideline-recommended regimens, however, HDDT is much safer.
